What bottleneck? New strategies for a better glycosylation profile
Webinar Date/Time: Tue, May 21, 2024 11:00 AM EDT
Learn how to address pipeline-specific challenges with novel CE, MS and integrated icIEF-UV/MS workflows
Register Free: https://www.biopharminternational.com/bp_w/better-glycosylation-profile
Event Overview:
Glycan analysis provides key information on critical quality attributes that could affect stability, safety and efficacy of a protein therapeutic. Specific needs for understanding the glycosylation profiles change throughout the drug development process, but the requirement for high-resolution glycan information remains the same and is essential to help ensure product quality. Learn how to address pipeline-specific challenges to support rapid screening and in-depth characterization of complex therapeutics with novel CE, MS and integrated icIEF-UV/MS workflows:
Combining orthogonal glycan analysis techniques for a deeper understanding of a tri-specific protein
Michael McKinnon, Novartis, will discuss new strategies for glycan site localization that provide a more in-depth look at glycan composition at individual sites.
New approaches for high-throughput glycan analysis to support bioprocess development
Brian Wei, PhD, Sanofi, will discuss how to make time for innovation and accommodate increasing analytical demands during bioprocess development with strategies for rapid glycan analysis.
Key Learning Objectives:
- Confirm clipped species with middle-down analysis
- Uncover the benefits of electron activated dissociation (EAD) for glycan profile determination
- Streamline glycan characterization throughout the drug development pipeline with novel methods
Who Should Attend:
- Senior Scientists
- Lab Directors
- Analytical Development Scientists
- Bioprocess Development Scientists
Speakers:
Michael McKinnon
Scientist II
Novartis
Brian Wei, PhD
Senior Manager, BioProcess Analytics
Sanofi
Brian Wei, PhD joined Sanofi in 2021 as Senior Scientist and managed a Separation Science subgroup in BioProcess Analytics under global CMC development. Brian is responsible for managing a group to support various bioprocess testing and lead the separation science innovation to address the future analytical challenges.
Before joining Sanofi, Brian worked for Sciex, ProteinSimple, and BioVidria focusing on developing new separation technologies for new bio-instrumentations. During his academic years, Brian collaborated with multiple companies in instrumentation and microfluidic devices in addition to several pharma companies. He also collaborated with Mayo Clinic for analytical development using new technologies.
Brian earned a BS in Chemistry from the University of Detroit Mercy, a MS in Chemistry (Organocatalysis) from Oakland University and a PhD in Chemistry (Analytical/Organic/Chemical biology) from Purdue University.
Register Free: https://www.biopharminternational.com/bp_w/better-glycosylation-profile
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
July 25th 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
July 16th 2025Mechanistic toxicity hypothesis is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The authors highlight the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.
